Acetaldehyde (AcH) produced in the physiological metabolism of ethanol can be potentially toxic and immunomodulating. The antitumour activity of a suicide gene system using adenovirus delivered alcohol dehydrogenase (ADH) to convert ethanol to acetaldehyde inside cancer cells has been investigated in vitro and in vivo. In vitro experiments confirmed the toxicity of acetaldehyde to a number of tumour cell lines. Daudi lymphoma cells grown in normal media increased by Day 4 to 650% of their starting number, while those exposed to 250 mM, 500 mM and 1 mM acetaldehyde reached 138, 30 and 5% respectively. Adenocarcinoma cells appeared to be less sensitive with CMT-64 cells and HeLa cells numbering 105 and 53% of their starting number by Day 4 with 1 mM acetaldehyde. After transduction with an adenovirus containing the human ADH beta 2 cDNA, CMT-64 cells exposed to 20 mM ethanol had a reduction in number to 74% by Day 2 and to 36% by Day 4. In a preclinical model with Ad-ADH CMT-64 cells, mice exposed to daily pulses of ethanol for 5 days formed tumours only 30% on Day 6 and 42% on Day 13 of the volume of those in mice exposed to water.The ability of this easily administered suicide gene system to produce significant effects on cell proliferation in vivo suggests that further optimized development is warranted.
T he use of antibody (ADEPT) and gene (GDEPT) directed enzyme-prodrug therapy systems to selectively produce cytotoxic agents within malignant or other target cells is well established in experimental therapeutics. 1 A number of prodrug toxin systems including; nitroreductase, 2 cytosine deaminase, 3 horseradish peroxidase, 4 thymidine kinase 5 and cytochrome P450 6 have been described, which convert relatively nontoxic prodrugs to potent cytotoxic agents.
We have investigated an alternative approach to the GDEPT system based on prolonged exposure to acetaldehyde generated from the metabolism of ethanol. Acetaldehyde is a well-recognized toxin producing singlestrand DNA breaks 7 and protein adducts. 8 While not previously described as a therapeutic agent, the ability of prolonged acetaldehyde exposure to damage or inhibit cell growth in vitro [9] [10] [11] and in vivo is well characterized. 12 The physiological metabolism of alcohol takes place primarily within the liver where ethanol is converted to acetaldehyde, mainly via the action of alcohol dehydrogenase. Acetaldehyde is then converted rapidly to acetylCoa via the action of aldehyde dehydrogenase (ALDH) predominantly by ALDH2 in hepatocytes. 13, 14 As a result of the high level of expression of both the ADH and ALDH enzymes within hepatocytes and other ethanol-metabolizing cell types, the accumulation of acetaldehyde is restricted and cellular damage usually only occurs on protracted exposure. However, the use of gene delivery and expression systems to selectively enhance ADH activity in cells with naturally low levels of ALDH may allow the production of elevated levels of acetaldehyde. Prolonged exposure to high acetaldehyde concentrations could lead directly to cell death or promote synergistic cytotoxicity in targeted cells when combined with conventional chemotherapy agents.
Whilst the volatility of acetaldehyde (boiling point 221C) makes accurate assessment of toxicity in vitro difficult, a number of studies have demonstrated that chronic acetaldehyde exposure can have significant effects on cell growth and doubling times. Wickramasinghe and Malik 15 reported that the Raji lymphoma cell line exposed to 360 mM acetaldehyde for 6 days showed an increased doubling time from 20 to 48 hours with similar results seen in other lymphoid cell lines. Parallel results have been reported for the human colorectal cell line Caco-2 with a 150% increase in cell doubling time following exposure to 500 mM acetaldehyde for 3 days. 16 More recent studies using plasmid-mediated transfer of ADH genes into cells with low ALDH activity have demonstrated that intracellular production of acetaldehyde reaching concentrations of up to 600 mM can result in growth inhibition 10, 17, 18 and induction of apoptosis. 10, 19 To investigate the potential of intracellular acetaldehyde generation as a therapeutic approach, we have used the human beta 2 ADH enzyme. The characteristics of this enzyme include near-maximum activity at physiological pH, a V max 16-fold higher than the standard beta 1 enzyme and a K m for ethanol of 0.94 mM. 20 These parameters suggest that ADH beta 2 would be an effective option to produce acetaldehyde at a high rate from ethanol at physiologically sustainable concentrations.
The pharmacokinetics and metabolism of ethanol have been extensively investigated and the short term and chronic toxicities well described. Ethanol is freely soluble in water and distributes rapidly to the interior of cells by diffusion. The ability of humans to tolerate levels of ethanol in excess of the K m of the beta 2 ADH enzyme for protracted periods of time is documented in a number of publications [21] [22] [23] and numerous personal anecdotes. To give perspective on the concentrations of ethanol described, the current UK driving limit of 80 mg/100 ml equates to 17.4mmol/l.
Materials and methods

Cell lines and in vitro acetaldehyde toxicity assays
Standard tissue culture techniques were used to maintain Daudi, Jurkat, CMT-64, HeLa, Skov and VA-13 10 cells in tissue culture media þ 10% FCS in a 371C incubator. For in vitro cytotoxicity experiments, cells were seeded into 25-cm 2 flasks and incubated in tissue culture media containing dilutions of acetaldehyde, cisplatin or both. Flasks were not sealed during incubation and the tissue culture media and acetaldehyde/cisplatin were replaced daily. Viable cell counts were made using trypan blue exclusion and a standard haemocytometer.
ADH-containing adenovirus (Ad-ADH) construction and transduction
A human ADH beta 2 cDNA clone 24 constructed for prokaryotic protein expression (kind gift of Dr T Hurley, Indiana University, IN, USA) was used to construct the Ad-ADH. After the reintroduction of a Kozak consensus sequence by PCR primer addition, the integrity of the construct was confirmed by DNA sequencing. The new construct was then cloned into pShuttle-CMV as a Hind III-Xba I fragment and then transferred into replication deficient adenovirus serotype 5 using homologous recombination in Escherichia coli. Ad-ADH production was completed in human embryonic kidney 293 cells following standard methods 25 and purified by CsCl banding. HeLa or CMT-64 cells were placed into six well tissue culture plates in 4 ml of media at 5 Â 10 5 per well. After overnight incubation, the cells were washed twice with PBS and then incubated with virus (HeLa MOI 100, CMT-64 MOI 500-1000 PFU) at 371C for 1 hour diluted in 1 ml of serum-free media. Following addition of 3 ml of complete tissue culture medium, the cells were incubated overnight, assayed for ADH activity and used for experiments as described below.
ADH activity spectrophotometer assay
The ADH activity of native and adenovirus transduced cells was assessed using a spectrophotometer assay following the method outlined by Crow et al. 26 . In brief, approximately 5 Â 10 5 cells were lysed in 1 ml of 0.05 M pyrophosphate buffer pH 8.8 containing 0.1% Triton X-100. 400 ml of cell lysate was added to 800 ml of ADH assay buffer comprising 0.025 M pyrophosphate buffer, 7.5 mM NAD and 5% ethanol. The change in absorbance at 340 nm resultant from the production of NADH was recorded on a Cecil 1020 s spectrophotometer.
Ad-ADH cytotoxicity assays
A total of 5 Â 10 5 cells transduced with Ad-ADH were seeded into 25-cm 2 flasks and grown in 5 ml of tissue culture media with ethanol, 4-MP (the ADH inhibitor 4-methylpyrazole 10 mmol/l (Sigma, Poole, UK) cisplatin or combinations. As a positive control VA-13 cells, the human hepatocellular carcinoma cell line HepG2 stably transfected with a murine ADH gene were employed in parallel. The lids to these flasks were sealed and the numbers of cells counted at intervals by trypan blue exclusion and a haemocytometer.
In vivo assessment of Ad-ADH ethanol-mediated toxicity
The animal experiment was approved by the Cancer Research UK animal use and safety committee and the Home Office before initiation. On the day prior to injection, 6 Â 10 6 CMT-64 cells were transduced with the Ad-ADH virus in vitro, then on Day 0 adult C57B/6 mice received s.c. injections in the flank of 5 Â 10 5 Ad-ADH CMT-64 cells (groups 1 and 2) or mock-infected CMT-64 cells (groups 3 and 4) suspended in 100 ml of PBS. On Days 0-4 groups 1 and 3 were injected with 500 ml of 12% ethanol (2 g/kg) solution i.p. and groups 2 and 4 received 500 ml of water i.p., there were six mice in each group. Tumour volume was estimated twice weekly using the formula: volume ¼ (length Â width Â width) Â (3.142/6).
Results
In vitro acetaldehyde-and cisplatin-mediated toxicity
The effect of prolonged acetaldehyde exposure on the growth of five tumour cell lines is demonstrated in Figure 1 . While Daudi lymphoma cells grown in normal tissue culture media increased in number by Day 4 to 650% of their starting number, those treated with acetaldehyde showed a dose-dependent reduction in proliferation reaching 138% in 250 mM acetaldehyde, 30% in 500 mM and only 5% for those treated with 1 mM. The Jurkat T-cell line showed similar results, but with no viable cells in the 1 mM treated group by Day 4. The adenocarcinoma cell lines Skov, HeLa and CMT-64 showed lesser but significant degrees of toxicity. By Day 4, the CMT-64 cells in normal media had reached 868% of their starting number, 786% in 250 mM AcH, 612% in 500 mM AcH but only 105% in 1 mM.
In Figure 2 , the effects of in vitro exposure to acetaldehyde and cisplatin on the cell lines are demonstrated. After 2 days the lymphoid cells exposed to 500 mM acetaldehyde show a reduced proliferation at 60% (Daudi) and 126% (Jurkat) of their starting numbers, while cisplatin 2.5 mM reduces their numbers to 65% and 60%, the two agents in combination produced a fall to 18% and 13% of starting numbers. Similarly, the results for the adenocarcinoma cells also show an additive effect from exposure to both drugs with 1 mM acetaldehyde restricting growth of the CMT-64 cells to 92% of the starting number, 5 mM cisplatin reducing to 41% and the combination to 15%.
Adenovirus Ad-ADH construction
The integrity of the addition of the Kozak sequence to the ADH beta2 cDNA construct prior to incorporation in the adenovirus was checked by DNA sequencing. The sequence of the entire construct was verified by comparison with those previously obtained (Dr T Hurley, personal communication). The correct molecular weight of the ADH protein produced by the adenovirus was confirmed by Western blotting of infected cells using a rabbit polyclonal anti-ADH serum (data not shown). The functional activity of the ADH construct was assessed with comparison of native and Ad-ADH infected CMT-64 cells in a spectrophotometer assay. This demonstrated 
Ad-ADH ethanol cytotoxicity assays
The effect of ethanol exposure on the growth of the native CMT-64, Ad-ADH-transduced CMT-64 cells and ADHtransfected VA-13 cells is demonstrated in Figure 3a .
With the native CMT-64 cells, the addition of ethanol or ethanol and 4-MP had no significant effect on cell numbers with increases in all groups from to approximately 250% of their starting number by Day 2. In contrast, the Ad-ADH CMT-64 (500:1) cells on exposure to ethanol had a reduction in their rate of expansion to 184% of their starting number on Day 2 compared to an increase to 370% for those not exposed to ethanol. Cells transduced at an MOI of 1000:1 had clearer evidence of cytotoxicity with a reduction in cell number to 74%, which was similar to that observed with the ADHtransfected VA-13 cells. The addition of the competitive ADH inhibitor 4-MP is demonstrated to inhibit the cytotoxic effect of ethanol exposure to the Ad-ADH CMT-64 and ADH VA-13 cells. In Figure 3b , prolonged exposure of CMT-64 1000:1 cells to ethanol showed at Day 4 a reduction to 36% of the starting number, demonstrating that cell death in addition to growth inhibition has occurred.
Combined effects of ethanol and cisplatin on Ad-ADH cells
The results of combining ethanol/acetaldehyde-mediated cytotoxicity with the cytotoxic drug cisplatin are shown in Figure 4 . Ad-ADH CMT-64 cells grown in standard media increased to 240% of the starting number by Day 2, while those exposed to ethanol, cisplatin or both agents fell to 70%, 75% and 44% respectively. Similarly, Ad-ADH HeLa cells reached 290% by Day 2, while the cells exposed to ethanol, cisplatin or both reached 124%, 64% and 36% respectively.
In vivo growth inhibition
The results of the in vivo experiment are shown in Figure 5 . The administration of ethanol or water appears to have had no measurable effect on the growth of the wild-type CMT-64 cells. The mean tumour volumes on days 6 and ADH/ethanol gene therapy P Savage et al 13 were 0.1645 and 0.514 cm 3 for the ethanol-treated mice (group 3) compared to 0.1455 and 0.536 cm 3 for the water-treated controls (group 4).
In contrast with the CMT-64 cells transduced with Ad-ADH, the mean size of the tumours in the mice exposed to ethanol was significantly smaller at 0.036 cm 3 (range 0.008-0.100 cm The experiment was halted on Day 14, when the mice with the larger tumours were killed. Within the Ad-ADH ethanol group, one mouse was continued through to Day 23 with no further increase in tumour size which measured 0.058 cm 3 on Day 10 and Day 23.
Discussion
The concept of targeted enzyme prodrug systems that convert relatively nontoxic agents into a potent cytotoxic drugs at the site of the tumor or other target cells was originally described over 30 years ago. 27 This approach should offer an elegant method to selectively deliver cytotoxic therapies either as gene (GDEPT)-or antibody (ADEPT)-based systems. However, at present, the clinical application of this technology is limited by a number of factors, of which achieving adequate delivery to sufficient target cells in vivo and the optimal characteristics of the prodrug toxin combination are the most challenging.
Using ethanol and a high-activity variant of the human alcohol dehydrogenase enzyme, we have explored a further approach to these systems examining a new prodrug/toxin combination that should be suitable for safe prolonged exposure and toxin generation in vivo.
Acetaldehyde, the primary metabolite of ethanol, is a well-recognized toxin and carcinogen, as confirmed by the results in Figure 1 , which show growth inhibition occurring in all the cell lines tested at levels of 250 mM. At higher concentrations, there is also evidence of direct cytotoxicity with the reduction in the starting cell number to 53.2% for HeLa, 5% for Daudi, 0% for Jurkat after 4 days exposure to acetaldehyde at 1 mM.
Previous studies have also demonstrated that acetaldehyde exposure can sensitise cancer cells to the effects of conventional cytotoxic agents. 28, 29 The experiments shown in Figure 2 confirm these findings with the exposure of Daudi cells and CMT-64 cells to the combination of cisplatin and acetaldehyde resulted in greater cell killing than to either agent alone.
To examine intracellular acetaldehyde production as a therapeutic strategy, we constructed an adenovirus (Ad-ADH) containing the human beta 2 ADH gene. This allele was chosen as it has a maximum enzymatic rate approximately 16-fold higher than the usual human ADH enzymes at 'physiological' ethanol concentrations. 20 While lymphoid cells would appear ideal for testing the Ad-ADH system, the routine introduction of simple Ad5 constructs into lymphoid cells is currently difficult to achieve. 30 In Figure 3a and b, the effects of the enhanced ethanol metabolism and acetaldehyde production on the growth and viability of wild type and Ad-ADH-transduced CMT-64 cells is shown. Native CMT-64 cells are unaffected by ethanol exposure while transduction with Ad-ADH leads to slowing of cell division and cell death, which was enhanced with either higher ratios of virus or longer exposure to ethanol. The blocking of this effect by the ADH inhibitor 4-MP confirms the role of acetaldehyde production in producing this cytotoxicity. Overall, these effects on CMT-64 cell growth and viability from transduction with Ad-ADH are similar to those demonstrated with the VA-13 cells that are stably transfected 31 and induction of apoptosis 11 on exposure to ethanol. The accurate assessment of the cytotoxic effects of prolonged exposure to acetaldehyde is extremely difficult to quantify in vitro. Acetaldehyde is volatile (bp 221C) rapidly evaporating with a T 1/2 of 30 minutes from tissue culture conditions. 32 Additionally, previous ADH transfectant studies have shown in cell culture that the ethanol concentration falls to below the K m of the enzyme within 2-3 days so making the in vitro assessment of chronic acetaldehyde production difficult. Unfortunately, the technology to measure acetaldehyde concentrations accurately is complex and not readily available, so we were unable to fully investigate the effects of prolonged ethanol and acetaldehyde exposure.
To obtain more clinically relevant data, we used a simple preclinical model, that examined the growth and viability of native and Ad-ADH transduced CMT-64 cells in mice exposed to ethanol for 5 days.
The results shown in Figure 5 demonstrate that administration of ethanol to C57 mice bearing wild-type CMT-64 cells has no significant effect on their tumour growth. In contrast, the administration of ethanol to the mice with Ad-ADH CMT-64 cells produced a significant delay in tumour growth with the median size of the ethanol-treated mice being 30% of the size of the watertreated controls on Day 6 and 42% on Day 13. Of interest, the tumour size in one of the experimental groups remained stable at 0.058 cm 3 through to Day 23. While these modest preliminary data are encouraging, it is likely that the mice received less than optimal ethanol exposure for continual ADH activity. Information from other groups suggests that mice metabolize ethanol five times faster than humans. 33 Two studies in C57 mice demonstrated that blood ethanol levels fell to below the limit of detection within 6-7 hours after i.p. ethanol injections of 3.7-3.8 g/kg. 34, 35 This would suggest that the mice in this current study, which only received 2 g/kg, had therapeutically useful blood ethanol concentrations for only a few hours each day, so receiving short pulses of acetaldehyde rather than continual exposure.
While measuring the concentration of acetaldehyde produced within the Ad-ADH transduced cells in vivo was not possible, it is probable that levels in the 500 mM to 1 mM range could be produced. This would be supported by the in vitro data that showed significant growth inhibition of CMT-64 cells only occurred at concentrations of over 500 mM. Additionally, clinical data from volunteers consuming alcohol in conjunction with an hepatic ALDH inhibitor showed systemic concentrations of acetaldehyde of up to 240 mM. 36, 37 With the considerable extrahepatic dilution, this would suggest that intrahepatic and intrahepatocyte concentrations should be considerably higher.
In addition to the direct toxic effects, acetaldehyde exposure can also produce immunological effects that may be therapeutically useful. The action of acetaldehyde on proteins produces alterations in their structure that allows acetaldehyde damaged cells to be recognized by both autoantibodies 38 and cytotoxic T cells. 39, 40 These mechanisms, which are similar to those involved in the pathogeneses of alcoholic cirrhosis, may offer a chance for upregulation by vaccination, thus producing effective immune responses that distinguish acetaldehyde-damaged tumour cells from healthy nonmalignant cells.
It is likely for this system and other suicide gene systems to be of clinical value that a high proportion of target tumour cells would need to be transduced. Recent developments in gene delivery systems using specific receptor binding 41 and tissue/malignancy-specific transcription 42 may allow sufficient improvement in gene delivery to allow this system to be positively assessed in a clinical system. The relative lack of clinically significant toxicity between alcohol and the majority of chemotherapy agents 43 suggests that this approach to enzyme prodrug therapy could safely be combined with most conventional chemotherapy drugs potentially with synergistic results as shown in Figure 4 .
Systemic acetaldehyde toxicity is unlikely to occur, while intratumoral concentrations of over 1 mM may be generated, the effect of venous dilution and rapid hepatic metabolism would reduce concentrations below the 40-60 mM level described for systemic acetaldehyde toxicity. 39 The ability to selectively express ADH and thus produce acetaldehyde within malignant, infected or other diseased cells may allow selective cytotoxicity to be produced with an economic, simple and well-tolerated system as either a monotherapy or in combination with conventional cytotoxic agents. This system should allow prolonged action, be effective against both dividing and nondividing cells and be safe and simple to administer as a monotherapy or in conjunction with conventional chemotherapy drugs. Currently, studies are ongoing to generate a replicating adenovirus and to use higher and more prolonged ethanol exposure in the preclinical model that will yield more information.
